Keystone Resort Floorplan
- Meeting Program
- Abstract Information
- Registration Information
- Scholarships / Awards
- My Account
NOTES:
This meeting will be conducted in English.
All programs are subject to change. Check this site for updates.
This meeting is part of the Global Health Series
Download Flyer
This meeting will be conducted in English.
All programs are subject to change. Check this site for updates.
This meeting is part of the Global Health Series
Download Flyer
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Tuesday, June 6 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Saturday, June 10 with a closing plenary session from 17:00 to 19:00, followed by a social hour. We recommend return travel on Sunday, June 11 in order to fully experience the meeting.
TUESDAY, JUNE 6
WEDNESDAY, JUNE 7
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
THURSDAY, JUNE 8
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
FRIDAY, JUNE 9
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
SATURDAY, JUNE 10
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
SUNDAY, JUNE 11
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Tuesday, June 6 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Saturday, June 10 with a closing plenary session from 17:00 to 19:00, followed by a social hour. We recommend return travel on Sunday, June 11 in order to fully experience the meeting.
TUESDAY, JUNE 6
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:30
Welcoming Remarks and Keystone Session (Joint)
*
Facundo D. Batista,
Massachusetts Institute of Technology and Harvard University, USA
*
Hanneke Schuitemaker,
Janssen Vaccines & Prevention B.V., Netherlands
William Schief,
The Scripps Research and IAVI, USA
Germline Targeting Strategies: mRNA EOD/Trimer Studies
Germline Targeting Strategies: mRNA EOD/Trimer Studies
Rafi Ahmed,
Emory University School of Medicine, USA
B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers
B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers
Coffee Break
09:50—11:30
How B Cells Function in Infectious Diseases (Joint)
*
Frances E. Lund,
University of Alabama at Birmingham, USA
Shane Crotty,
La Jolla Institute for Immunology, USA
Immune Memory to SARS-CoV-2 and COVID-19 Vaccines, and Lessons for HIV Vaccine Development
Immune Memory to SARS-CoV-2 and COVID-19 Vaccines, and Lessons for HIV Vaccine Development
Michel C. Nussenzweig,
HHMI/Rockefeller University, USA
Development of B Cell Memory
Development of B Cell Memory
Susan Moir,
NIAID, National Institutes of Health, USA
B Cell Responses to Chronic and Repeated Antigen Exposures: Lessons from HIV and SARS-CoV-2
B Cell Responses to Chronic and Repeated Antigen Exposures: Lessons from HIV and SARS-CoV-2
11:30—13:00
Hands-On Computer Workshop on Los Alamos HIV Sequence Database and Tools (Joint)
*
Brian T. Foley,
Los Alamos National Lab, USA
14:30—16:30
Workshop 1
Daniel Morris,
University of Pennsylvania, USA
Glycan-deficient SHIVs to Elicit Broadly Neutralizing HIV-1 Antibodies in Macaques
Glycan-deficient SHIVs to Elicit Broadly Neutralizing HIV-1 Antibodies in Macaques
*
Kevin Wiehe,
Duke University, USA
Mutation-guided Vaccine Design: A Process for Developing Boosting Immunogens for HIV Broadly Neutralizing Antibody Induction
Mutation-guided Vaccine Design: A Process for Developing Boosting Immunogens for HIV Broadly Neutralizing Antibody Induction
Ashwin Nicholas Skelly,
University of Pennsylvania, USA
Elicitation of V3 Glycan-directed Cross-neutralizing Antibodies in Sequentially Immunized, SHIV-infected Rhesus Macaques
Elicitation of V3 Glycan-directed Cross-neutralizing Antibodies in Sequentially Immunized, SHIV-infected Rhesus Macaques
Yoann Aldon,
Amsterdam UMC, Netherlands
gp41-free Native-like HIV-1 Env Trimers: Beyond Structure-guided Design
gp41-free Native-like HIV-1 Env Trimers: Beyond Structure-guided Design
Mitch Brinkkemper,
University of Amsterdam, Netherlands
Highly Stabilized and Densily Glycosylated HIV-1 Env Trimers Co-displayed on Two-component Nanoparticles do not Elicit bNAb Responses
Highly Stabilized and Densily Glycosylated HIV-1 Env Trimers Co-displayed on Two-component Nanoparticles do not Elicit bNAb Responses
Maria Belen Palacio,
Wistar Institute, USA
A Novel Strategy to Generate Knock-in Mice for HIV Vaccine Development
A Novel Strategy to Generate Knock-in Mice for HIV Vaccine Development
Parham Ramezani-Rad,
La Jolla Institute for Immunology, USA
A Membrane-Bound Native-like HIV Envelope Trimer mRNA Vaccine in Animal Models
A Membrane-Bound Native-like HIV Envelope Trimer mRNA Vaccine in Animal Models
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
14:30—16:30
Workshop 1: B Cells in Infection and Inflammation
*
Michelle A. Linterman,
Babraham Institute, UK
*
Elliott SoRelle,
Duke University, USA
Matthew C. Woodruff,
Emory University, USA
Acute Tolerance Loss and Naive-Derived Autoantibodies: Implications for COVID-19 and Beyond
Acute Tolerance Loss and Naive-Derived Autoantibodies: Implications for COVID-19 and Beyond
Xin Gao,
JCSMR, the Australian National University, Australia
B Cells Engaging with Whole Parasites can take up Bystander Surface Antigens to Obtain Help from T Cells with Multiple Specificities
B Cells Engaging with Whole Parasites can take up Bystander Surface Antigens to Obtain Help from T Cells with Multiple Specificities
Zgjim Osmani,
Erasmus University Medical Center, Netherlands
The Distinct Effects of HBsAg in Blood and Liver of Chronic Hepatitis B Patients are Restricted to Memory B-, NK-, and CD8 T Cell Subsets
The Distinct Effects of HBsAg in Blood and Liver of Chronic Hepatitis B Patients are Restricted to Memory B-, NK-, and CD8 T Cell Subsets
Mohini K. Gray,
Centre for Inflammation Research, UK
CD11c+ve Double-negative-2 B Cells Constitute a Major Targetable Pathogenic B Cell Subset within the Diseased Rheumatoid Synovium
CD11c+ve Double-negative-2 B Cells Constitute a Major Targetable Pathogenic B Cell Subset within the Diseased Rheumatoid Synovium
Luke Muir,
University College London, UK
Small Transient Increases in HIV-1 Viral Load Induce a Potent Humoral Immune Response and Associated B Cell Dysfunction
Small Transient Increases in HIV-1 Viral Load Induce a Potent Humoral Immune Response and Associated B Cell Dysfunction
Daniel D. Pinschewer,
University of Basel, Switzerland
Follicular T Helper Cell Response and Antibody-mediated Viral Load Control in “Immunologically Tolerant” Congenitally Infected Mice
Follicular T Helper Cell Response and Antibody-mediated Viral Load Control in “Immunologically Tolerant” Congenitally Infected Mice
Ellen Shrock,
Harvard University, USA
Viral Epitope Profiling of COVID-19 Patients Reveals Cross-reactivity and Correlates of Severity
Viral Epitope Profiling of COVID-19 Patients Reveals Cross-reactivity and Correlates of Severity
17:00—19:00
Rational Vaccine Design
*
Marit van Gils,
Amsterdam UMC, Netherlands
Barton F. Haynes,
Duke University Medical Center, USA
Duke CHAVD Immunogen Design and Clinical Trials Results
Duke CHAVD Immunogen Design and Clinical Trials Results
Hannah R. Shrader,
National Institutes of Health Vaccine Research Center, USA
Short Talk: Engineering Multispecific HIV-1 Neutralizing Antibodies Based on Complementarity of CD4 Binding Site Broadly-Neutralizing Antibodies
Short Talk: Engineering Multispecific HIV-1 Neutralizing Antibodies Based on Complementarity of CD4 Binding Site Broadly-Neutralizing Antibodies
Manyuan Ma,
The Scripps Research, USA
Short Talk: An HIV Vaccine Initiated V2 Apex Broadly Neutralizing Antibody-like Responses in Non-human Primates
Short Talk: An HIV Vaccine Initiated V2 Apex Broadly Neutralizing Antibody-like Responses in Non-human Primates
Sean Callaghan,
The Scripps Research Institute, USA
Short Talk: Development of B Cell Lineage-based CAP256.SU HIV Germline-targeting Nanoparticle Immunogen that can Efficiently Engage V2-apex bnAb Precursors
Short Talk: Development of B Cell Lineage-based CAP256.SU HIV Germline-targeting Nanoparticle Immunogen that can Efficiently Engage V2-apex bnAb Precursors
Joshua Tan,
NIAID, National Institutes of Health, USA
Short Talk: Broadly Neutralizing Antibodies Target the Coronavirus Fusion Peptide
Short Talk: Broadly Neutralizing Antibodies Target the Coronavirus Fusion Peptide
Torben Schiffner,
Leipzig University, Germany
Short Talk: Vaccine Induction of Broadly Neutralizing Antibody Precursors to HIV gp41
Short Talk: Vaccine Induction of Broadly Neutralizing Antibody Precursors to HIV gp41
Christopher A. Cottrell,
The Scripps Research Institute, USA
Short Talk: Germline-targeting, mRNA-delivered, Nanoparticle Immunogens Prime and Boost VRC01-class B Cell Responses in Stringent Mouse Models
Short Talk: Germline-targeting, mRNA-delivered, Nanoparticle Immunogens Prime and Boost VRC01-class B Cell Responses in Stringent Mouse Models
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
17:00—19:00
Control and Modulation of B Cell Responses
*
Shane Crotty,
La Jolla Institute for Immunology, USA
*
Pavel Tolar,
University College London, UK
Frances E. Lund,
University of Alabama at Birmingham, USA
Regulation of Effector Memory B Cell Development and Function
Regulation of Effector Memory B Cell Development and Function
Mauro N. Gaya,
Luminy Center for Immunology in Marseille, France
B Cell Immunity in the Lung Airways
B Cell Immunity in the Lung Airways
Jenny Jiang,
University of Pennsylvania, USA
High-Throughput and High-Dimensional Profiling of Antigen-Specific T cells
High-Throughput and High-Dimensional Profiling of Antigen-Specific T cells
Renan Villanova Homem de Carvalho,
Rockefeller University, USA
Short Talk: Clonal Replacement Sustains Long-lived Germinal Centers Primed by Respiratory Viruses
Short Talk: Clonal Replacement Sustains Long-lived Germinal Centers Primed by Respiratory Viruses
Martin Turner,
Babraham Institute, UK
Short Talk: Post-transcriptional Regulation of B Cell Selection in Germinal Centres
Short Talk: Post-transcriptional Regulation of B Cell Selection in Germinal Centres
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Rational Vaccine and Adjuvant (Joint)
*
Susan Moir,
NIAID, National Institutes of Health, USA
Darrell J. Irvine,
Massachusetts Institute of Technology, USA
Controlled Modulation of B Cell Responses
Controlled Modulation of B Cell Responses
Michelle A. Linterman,
Babraham Institute, UK
Spatial Dysregulation of T Follicular Helper Cells Impairs Vaccine Responses in Aging
Spatial Dysregulation of T Follicular Helper Cells Impairs Vaccine Responses in Aging
Coffee Break
Andrew B. Ward,
The Scripps Research Institute, USA
HIV Structural Studies and Implications for Vaccine Development
HIV Structural Studies and Implications for Vaccine Development
Mangala Rao,
Walter Reed Army Institute of Research, USA
Short Talk: HIV-1 gp120 Envelope Protein Mixed with Army Liposome Formulation ALFQ Induces Potent and Durable Antigen-specific Humoral Immune Responses in Nonhuman Primates
Short Talk: HIV-1 gp120 Envelope Protein Mixed with Army Liposome Formulation ALFQ Induces Potent and Durable Antigen-specific Humoral Immune Responses in Nonhuman Primates
Sudhir Pai Kasturi,
Emory University, USA
Short Talk: B Cell Receptor Sequencing of Blood and Bone Marrow Antibody Secreting Cells Reveals Higher Clonal Overlap and Superior Ability of 3M-052-alum
Short Talk: B Cell Receptor Sequencing of Blood and Bone Marrow Antibody Secreting Cells Reveals Higher Clonal Overlap and Superior Ability of 3M-052-alum
Stephen J. Elledge,
Harvard Medical School, USA
Short Talk: Germline-encoded Amino Acid-binding Motifs Drive Immunodominant Public Antibody Responses
Short Talk: Germline-encoded Amino Acid-binding Motifs Drive Immunodominant Public Antibody Responses
Daniel Lingwood,
Harvard Medical School, USA
Short Talk: Allelic Polymorphism Controls Immune Tolerance and Vaccine-Elicitation of Human Broadly Neutralizing Antibodies Against Influenza Virus
Short Talk: Allelic Polymorphism Controls Immune Tolerance and Vaccine-Elicitation of Human Broadly Neutralizing Antibodies Against Influenza Virus
11:00—12:30
Michelson Awards Luncheon
Jenna Guthmiller,
University of Colorado SOM, USA
Mapping Preexisting Mucosal B Cell Specificities Engaged by Potential Universal Influenza Vaccines
Mapping Preexisting Mucosal B Cell Specificities Engaged by Potential Universal Influenza Vaccines
Romain Guyon,
University of Oxford, UK
Demonstration of New Single-dose Vaccine Technology towards a First-in-Man Clinical Application
Demonstration of New Single-dose Vaccine Technology towards a First-in-Man Clinical Application
Brittany Hartwell,
University of Minnesota, USA
Engineering Albumin-hitchhiking Intranasal Vaccines with Enhanced Transmucosal Uptake to Promote Immunity
Engineering Albumin-hitchhiking Intranasal Vaccines with Enhanced Transmucosal Uptake to Promote Immunity
Joshua Tan,
NIAID, National Institutes of Health, USA
Searching for Common Ground: The Conserved Coronavirus Fusion Peptide is a Target of Broadly Neutralizing Antibodies
Searching for Common Ground: The Conserved Coronavirus Fusion Peptide is a Target of Broadly Neutralizing Antibodies
14:30—16:30
Workshop 2
Christopher A. Gonelli,
National Institutes of Health, USA
Apparent Protection from SIV-specific bNAb Immunoprophylaxis May Represent Delayed Viremia after Subclinical SIV Infection in Rhesus Macaques
Apparent Protection from SIV-specific bNAb Immunoprophylaxis May Represent Delayed Viremia after Subclinical SIV Infection in Rhesus Macaques
Flavio Matassoli,
National Institutes of Health, USA
Assessing the Frequency of Naïve B Cells Potentially Capable of Producing Broad Neutralizing Antibodies for HIV
Assessing the Frequency of Naïve B Cells Potentially Capable of Producing Broad Neutralizing Antibodies for HIV
Daniel Reeves,
Fred Hutchinson Cancer Research Center, USA
VRC01 Reduced Breakthrough Viral Loads in the HIV Antibody Mediated Prevention (AMP) Studies
VRC01 Reduced Breakthrough Viral Loads in the HIV Antibody Mediated Prevention (AMP) Studies
Stephen A. Migueles,
National Institutes of Health, USA
HIV Vaccines Induce Hypofunctional CD8+ T Cells with Low Structural Avidity
HIV Vaccines Induce Hypofunctional CD8+ T Cells with Low Structural Avidity
Dania Figueroa Acosta,
Icahn School of Medicine at Mount Sinai, USA
Abundance of Uncleaved Env on the Cell Surface is Modulated by Endocytic Recycling and Alters the Sensitivity of Cell-to-cell Infection
Abundance of Uncleaved Env on the Cell Surface is Modulated by Endocytic Recycling and Alters the Sensitivity of Cell-to-cell Infection
Sam Charaf,
NIAID, USA
The Level of VRC01-class Precursors Determines the Efficacy of Sequential Immunization Regimens to Elicit VRC01-Class Broadly Neutralizing Antibodies in Transgenic Mice
The Level of VRC01-class Precursors Determines the Efficacy of Sequential Immunization Regimens to Elicit VRC01-Class Broadly Neutralizing Antibodies in Transgenic Mice
*
Morgane Rolland,
Henry M Jackson Foundation, USA
HIV-1 Acute Infection Multiple Founder Variants as Vaccine Candidates
HIV-1 Acute Infection Multiple Founder Variants as Vaccine Candidates
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
14:30—16:30
Workshop 2: Dynamics of B Cell Memory
*
Mauro N. Gaya,
Luminy Center for Immunology in Marseille, France
*
Kim Good-Jacobson,
Monash University, Australia
Brian J. Laidlaw,
Washington University in St. Louis, USA
CD62L Expression Marks a Functionally Distinct Subset of Memory B Cells in Mice and Humans
CD62L Expression Marks a Functionally Distinct Subset of Memory B Cells in Mice and Humans
Pascal Chappert,
Institut Necker Enfants Malades, France
Omicron BA.1 Breakthrough Infection Drives Long-term Remodeling of the Memory B Cell Repertoire in Vaccinated Individuals
Omicron BA.1 Breakthrough Infection Drives Long-term Remodeling of the Memory B Cell Repertoire in Vaccinated Individuals
Manon Termote,
Karolinska Institutet, Sweden
Antigen Affinity and Pre-existing Antibodies Dictate Memory B Cell Entry into Secondary Germinal Centers
Antigen Affinity and Pre-existing Antibodies Dictate Memory B Cell Entry into Secondary Germinal Centers
Allyssa Phelps,
McMaster University, Canada
Pathogenic IgE-fated B Cell Memory Retains Functional Plasticity
Pathogenic IgE-fated B Cell Memory Retains Functional Plasticity
Eva Conde Garcia,
Regeneron Pharmaceuticals, USA
Chronic Allergen Exposure Induces Allergen-specific IgA via Distinct Pathways that Generate IgAs of Different Affinity, with Potential Consequences for the Allergic Response
Chronic Allergen Exposure Induces Allergen-specific IgA via Distinct Pathways that Generate IgAs of Different Affinity, with Potential Consequences for the Allergic Response
Zhixin Jing,
National Institute of Allergy and Infectious Diseases, USA
Fine-tuning Spatial-temporal Dynamics and Surface Receptor Expression Support Plasma Cell-intrinsic Longevity
Fine-tuning Spatial-temporal Dynamics and Surface Receptor Expression Support Plasma Cell-intrinsic Longevity
Haewon Sohn,
NIAID, National Institutes of Health, USA
The Mechanosensitive Ion Channel Piezo1 is Required for B Cell Responses to Membrane-presented Antigens
The Mechanosensitive Ion Channel Piezo1 is Required for B Cell Responses to Membrane-presented Antigens
Theresa Pinter,
IMP, Austria
Control of B Cell Development and Function by the SAGA Complex
Control of B Cell Development and Function by the SAGA Complex
17:00—19:00
Translational HIV Vaccine Research
Alejandro Balazs,
Massachusetts General Hospital, USA
Antibody-mediated Prevention of Vaginal HIV Transmission is Dictated by IgG Subclass in Humanized Mice
Antibody-mediated Prevention of Vaginal HIV Transmission is Dictated by IgG Subclass in Humanized Mice
*
Devin Sok,
International AIDS Vaccine Initiative, USA
IAVI Vaccine and Passive Antibody Trials in Africa
IAVI Vaccine and Passive Antibody Trials in Africa
Louis J. Picker,
Oregon Health & Science University, USA
Understanding the “Control and Clear” Efficacy of RhCMV/SIV Vaccine Vectors
Understanding the “Control and Clear” Efficacy of RhCMV/SIV Vaccine Vectors
Karlijn van der Straten,
Amsterdam UMC, Netherlands
Short Talk: Safety, Tolerability and Immunogenicity of a Phase 1 HIV Vaccination Trial using ConM SOSIP.v7 gp140, Adjuvanted with MPLA Liposomes
Short Talk: Safety, Tolerability and Immunogenicity of a Phase 1 HIV Vaccination Trial using ConM SOSIP.v7 gp140, Adjuvanted with MPLA Liposomes
Shuishu Wang,
NIAID, National Institutes of Health, USA
Short Talk: Prefusion-Stabilized BG505 Envelope Trimer Elicits Fusion Peptide-Directed HIV-Neutralizing Antibodies in Humans
Short Talk: Prefusion-Stabilized BG505 Envelope Trimer Elicits Fusion Peptide-Directed HIV-Neutralizing Antibodies in Humans
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
17:00—19:00
Antigen Driven Activation, Selection and Metabolic Re-Programming
*
Brian J. Laidlaw,
Washington University in St. Louis, USA
*
Martin Turner,
Babraham Institute, UK
Pavel Tolar,
University College London, UK
Regulation of Antigen Persistence in Germinal Centers
Regulation of Antigen Persistence in Germinal Centers
Gabriel D. Victora,
Rockefeller University, USA
Evolution of Antibody Responses to Infection and Immunization
Evolution of Antibody Responses to Infection and Immunization
Stephanie C. Eisenbarth,
Northwestern Univ Feinberg Sch Med, USA
The IgA B Cell Response in the Gut to Food Antigens
The IgA B Cell Response in the Gut to Food Antigens
Nuria Martínez-Martín,
CBMSO-CSIC, Spain
Short Talk: Defective Mitochondria Remodelling in B Cells Leads to an Aged Immune Response
Short Talk: Defective Mitochondria Remodelling in B Cells Leads to an Aged Immune Response
Henry Sutton,
La Jolla Institute of Immunology, USA
Short Talk: The Benefit of Long-lasting Germinal Centers to Antigen-specific B Cell Responses
Short Talk: The Benefit of Long-lasting Germinal Centers to Antigen-specific B Cell Responses
19:00—20:00
On Own for Dinner
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Broadly Neutralizing Antibodies and Passive Immunization Against HIV and SARS-CoV-2
Marit van Gils,
Amsterdam UMC, Netherlands
Complementary Antibody Lineages Achieve Neutralization Breadth In An HIV-1 Infected Elite Neutralizer
Complementary Antibody Lineages Achieve Neutralization Breadth In An HIV-1 Infected Elite Neutralizer
*
Laura M. Walker,
Moderna, USA
Evolution of Antibody Immunity Following Omicron Breakthrough Infection
Evolution of Antibody Immunity Following Omicron Breakthrough Infection
Coffee Break
Margaret Juliana McElrath,
Fred Hutchinson Cancer Research Center, USA
HVTN Updates: Adjuvants and SOSIP Trimer Trials
HVTN Updates: Adjuvants and SOSIP Trimer Trials
Matheus Oliveira de Souza,
Ragon Institute of MGH, MIT and Harvard, USA
Short Talk: Engineering VRC07-523-LS FR3-03 for Enhanced HIV-1 Neutralization Potency and Breadth
Short Talk: Engineering VRC07-523-LS FR3-03 for Enhanced HIV-1 Neutralization Potency and Breadth
Greg Whitehill,
University of Pennsylvania, USA
Short Talk: Neutralizing Antibodies Selective for Autologous Plasma Virus Develop after Early ARTi
Short Talk: Neutralizing Antibodies Selective for Autologous Plasma Virus Develop after Early ARTi
Alexandra Trkola,
University of Zürich, Switzerland
Short Talk: Multi-specificity Creates HIV-1 Elite Broadly Neutralizing Capacity
Short Talk: Multi-specificity Creates HIV-1 Elite Broadly Neutralizing Capacity
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
08:00—11:00
Affinity Based Selection and Fate Decisions: Long Lived Plasma Cells and Memory B Cells
*
Gabriel D. Victora,
Rockefeller University, USA
Frances Eun-Hyung Lee,
Emory University, USA
Differential Ability to Modulate Antibody Secretion in Human Long-lived Plasma Cells
Differential Ability to Modulate Antibody Secretion in Human Long-lived Plasma Cells
Oliver Bannard,
University of Oxford, UK
Plasma Cell Differentiation during Infection
Plasma Cell Differentiation during Infection
Coffee Break
Tomohiro Kurosaki,
Osaka University, Japan
Requirement for Optimal BCR Signal Strength in Efficient Positive Selection of Germinal Center (GC) B Cells
Requirement for Optimal BCR Signal Strength in Efficient Positive Selection of Germinal Center (GC) B Cells
Vassilis Glaros,
Karolinska Institutet, Sweden
Short Talk: The Marginal Zone B Cell Molecular Program is a Niche-induced State Associated with Long-term Persistence of B Cell Memory
Short Talk: The Marginal Zone B Cell Molecular Program is a Niche-induced State Associated with Long-term Persistence of B Cell Memory
Kim Good-Jacobson,
Monash University, Australia
Short Talk: Formation and Plasticity of Memory B Cell Epigenetic Identity in Chronic Viral Infection
Short Talk: Formation and Plasticity of Memory B Cell Epigenetic Identity in Chronic Viral Infection
Sarah F. Andrews,
National Institutes of Health, USA
Short Talk: The B Cell Response to Influenza Vaccination is Shaped by Influenza Virus Exposure Fifty Years Ago
Short Talk: The B Cell Response to Influenza Vaccination is Shaped by Influenza Virus Exposure Fifty Years Ago
Christopher Risley,
UAB, USA
Short Talk: T-bet Regulates the Maintenance and ASC Differentiation Potential of the Lymph Node and Lung Effector Memory B Cell Compartments
Short Talk: T-bet Regulates the Maintenance and ASC Differentiation Potential of the Lymph Node and Lung Effector Memory B Cell Compartments
11:00—12:30
Hands-On Computer Workshop on Los Alamos HIV Immunology Database and Tools (Joint)
*
Brian T. Foley,
Los Alamos National Lab, USA
15:00—16:30
Career Roundtable (Joint)
Glenda E. Gray,
South African Medical Research Council, South Africa
Louis M. Staudt,
NCI, National Institutes of Health, USA
Erik Jongert,
GlaxoSmithKline, Belgium
Julie Ake,
Walter Reed Army Institute of Research, USA
Stephanie C. Eisenbarth,
Northwestern Univ Feinberg Sch Med, USA
Alejandro Balazs,
Massachusetts General Hospital, USA
17:00—19:00
Next Generation PrEP
*
Rebecca M. Lynch,
George Washington University, USA
S. Rahima Benhabbour,
University of North Carolina, USA
Harnessing Innovative Engineering to Desing the Next Generation Long-Acting PrEP
Harnessing Innovative Engineering to Desing the Next Generation Long-Acting PrEP
Jianliang Xu,
Georgia State University, USA
Superpotent Broadly Neutralizing Human-llama Bispecific Antibodies Against HIV-1
Superpotent Broadly Neutralizing Human-llama Bispecific Antibodies Against HIV-1
Madison Fox,
NIAID, NIH, USA
Potent Suppression of Viral Rebound after Analytical Treatment Interruption in ART-suppressed SHIV-infected Animals by a CD4 Binding Site bNAb
Potent Suppression of Viral Rebound after Analytical Treatment Interruption in ART-suppressed SHIV-infected Animals by a CD4 Binding Site bNAb
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
17:00—19:00
Activation and Redemption of the Autoreactive B Cell Repertoire in Autoimmune
*
Carola G. Vinuesa,
Francis Crick Institute, UK
*
Tomohiro Kurosaki,
Osaka University, Japan
Ignacio Sanz,
Emory University, School of Medicine, USA
B Cells and their Effector Progeny in Autoimmune Disease
B Cells and their Effector Progeny in Autoimmune Disease
Christopher C. Goodnow,
Garvan Institute of Medical Research, Australia
Virus-induced Autoantibodies: Redemption or Pathological Evolution through B Cell Mutations in V(D)J-regions and Lymphoma Driver Genes
Virus-induced Autoantibodies: Redemption or Pathological Evolution through B Cell Mutations in V(D)J-regions and Lymphoma Driver Genes
Jennifer L. Gommerman,
University of Toronto, Canada
B Cells and BAFF in Multiple Sclerosis
B Cells and BAFF in Multiple Sclerosis
Taiichiro Shirai,
Osaka University, Japan
Short Talk: Inhibition of the COMMD3/8 Complex Suppresses Humoral Immune Responses and Autoimmunity
Short Talk: Inhibition of the COMMD3/8 Complex Suppresses Humoral Immune Responses and Autoimmunity
Clara Young,
Garvan Institute, Australia
Short Talk: Precursor Self-reactivity and Lymphoma Gene Mutations Drive Pathogenic B Cell Clones in Autoimmune Hepatitis C Virus (HCV)-associated Cryoglobulinemic Vasculitis
Short Talk: Precursor Self-reactivity and Lymphoma Gene Mutations Drive Pathogenic B Cell Clones in Autoimmune Hepatitis C Virus (HCV)-associated Cryoglobulinemic Vasculitis
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Update on HIV Vaccine Trials
*
Julie Ake,
Walter Reed Army Institute of Research, USA
Hanneke Schuitemaker,
Janssen Vaccines & Prevention B.V., Netherlands
Ad26 Vaccines for COVID and HIV
Ad26 Vaccines for COVID and HIV
Hyman Scott,
University of California, San Francisco, USA
Priming Vaccine Regimen with Adjuvented 426c Core to Induce CD4bs Antibodies (HVTN 301)
Priming Vaccine Regimen with Adjuvented 426c Core to Induce CD4bs Antibodies (HVTN 301)
Coffee Break
Glenda E. Gray,
South African Medical Research Council, South Africa
Next Generation of Efficacy Studies; Vaccine Development in era of Long Acting PrEP
Next Generation of Efficacy Studies; Vaccine Development in era of Long Acting PrEP
Wilton B. Williams,
Duke University School of Medicine, USA
Short Talk: HIV Polyclonal Neutralizing Antibody Responses Elicited by gp41 MPER Peptide-Liposome in Humans
Short Talk: HIV Polyclonal Neutralizing Antibody Responses Elicited by gp41 MPER Peptide-Liposome in Humans
Benjamin Leach,
National Institutes of Health, USA
Short Talk: Low-Avidity CD8+ T Cells Induced by Ad5/HIV Vaccines Exhibit Impaired Cytotoxic Granule Polarization
Short Talk: Low-Avidity CD8+ T Cells Induced by Ad5/HIV Vaccines Exhibit Impaired Cytotoxic Granule Polarization
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
08:00—11:00
The Impact of Infectious Disease and Inflammation on the B Cell Compartment
*
Sarah F. Andrews,
National Institutes of Health, USA
Carola G. Vinuesa,
Francis Crick Institute, UK
Mechanisms Underpinning Human Systemic Autoimmunity: Lessons from Inborn Errors of Immunity
Mechanisms Underpinning Human Systemic Autoimmunity: Lessons from Inborn Errors of Immunity
Marion Pepper,
University of Washington, USA
B Cell Response in Malaria
B Cell Response in Malaria
Coffee Break
Facundo D. Batista,
Massachusetts Institute of Technology and Harvard University, USA
Cell Metabolic Re-Programming
Cell Metabolic Re-Programming
Cristian G. Beccaria,
San Raffaele Scientific Institute, San Raffaele Hospital, Italy
Short Talk: Deciphering the HBV Specific B Cell-mediated Immune Response in a Mouse Model of HBV Pathogenesis
Short Talk: Deciphering the HBV Specific B Cell-mediated Immune Response in a Mouse Model of HBV Pathogenesis
Lalit Kumar Dubey,
Queen Mary University of London, UK
Short Talk: B Cell-Stomal Crosstalk Govern Mesenteric Lymph Node Lymphangiogenesis during Intestinal Helminth Infection
Short Talk: B Cell-Stomal Crosstalk Govern Mesenteric Lymph Node Lymphangiogenesis during Intestinal Helminth Infection
Cherrelle Dacon,
National Institutes of Health, USA
Short Talk: Discovery of Human Monoclonal Antibodies against a Cryptic Epitope on the Plasmodium Falciparum Sporozoite Surface
Short Talk: Discovery of Human Monoclonal Antibodies against a Cryptic Epitope on the Plasmodium Falciparum Sporozoite Surface
14:30—16:30
Workshop 3
*
Alexandra Trkola,
University of Zürich, Switzerland
Yanique Serge Gillana Thomas,
Northwestern University, USA
Defining the Dynamics of SIV Infection and the Viral Reservoir from Early ART Initiation to Rebound using PET/CT Analysis and a Multi-scale Imaging Approach
Defining the Dynamics of SIV Infection and the Viral Reservoir from Early ART Initiation to Rebound using PET/CT Analysis and a Multi-scale Imaging Approach
Yuqi Zhou,
University of Pennsylvania, USA
Chimeric Antigen Receptors Enable Superior Control of HIV Replication by Rapid Killing of Infected Cells
Chimeric Antigen Receptors Enable Superior Control of HIV Replication by Rapid Killing of Infected Cells
Lutz Gieselmann,
Laboratory of Experimental Immunology Cologne, Germany
Large-scale Characterization of a Cohort of HIV-1 Elite Neutralizers Reveals a Novel Highly Broad and Potent CD4 Binding Site bNAb
Large-scale Characterization of a Cohort of HIV-1 Elite Neutralizers Reveals a Novel Highly Broad and Potent CD4 Binding Site bNAb
Kristen A. Rodrigues,
Massachusetts Institute of Technology, USA
Optimization of an Alum-anchored Clinical HIV Vaccine Candidate
Optimization of an Alum-anchored Clinical HIV Vaccine Candidate
Steven William de Taeye,
Amsterdam UMC, Netherlands
Afucosylated bNAbs Enhance Clearance of HIV-1 Infected Cells through NK Cell Mediated ADCC
Afucosylated bNAbs Enhance Clearance of HIV-1 Infected Cells through NK Cell Mediated ADCC
Nicholas Bayless,
Centivax Inc., USA
Use of Computationally Guided Vaccine Technology to Develop a Broad-Spectrum Vaccine Targeting HIV
Use of Computationally Guided Vaccine Technology to Develop a Broad-Spectrum Vaccine Targeting HIV
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
14:30—16:30
Workshop 3: Germinal Centers: Antibody Affinity Maturation and Differentiation
*
Oliver Bannard,
University of Oxford, UK
*
Nuria Martínez-Martín,
CBMSO-CSIC, Spain
Christopher James Jara,
Garvan Institute of Medical Research, Australia
Clonal Redemption of a Human IGHV4-34 Autoantibody in a Mouse Model
Clonal Redemption of a Human IGHV4-34 Autoantibody in a Mouse Model
Sharon Kagan Ben Tikva,
Weizmann Institute of Science, Israel
Myc Transcriptional Bursts Promote B Cell Selection by T Cells in Germinal Centers
Myc Transcriptional Bursts Promote B Cell Selection by T Cells in Germinal Centers
Laurine Binet,
University of Aix-Marseille, France
Single-cell and Spatial Analyses of Intermediate States in GC B to PC Differentiation
Single-cell and Spatial Analyses of Intermediate States in GC B to PC Differentiation
Avneesh Gautam,
Brigham and Women's Hospital, USA
Vast Antibody Affinity Birth Potential through Somatic Hypermutation
Vast Antibody Affinity Birth Potential through Somatic Hypermutation
Oliver Philip Skinner,
Peter Doherty Institute, University of Melbourne, Australia
Mapping B-cell Fate and Clonal Dynamics during Malaria
Mapping B-cell Fate and Clonal Dynamics during Malaria
Julia Zofia Adamska,
Stanford University, USA
Ablation of the RNA-Editing Enzyme ADAR1 in Germinal Center B Cells Results in Impaired Plasma Cell and Memory B Cell Formation
Ablation of the RNA-Editing Enzyme ADAR1 in Germinal Center B Cells Results in Impaired Plasma Cell and Memory B Cell Formation
Jaime L. Chao,
University of Washington, USA
Spatial Heterogeneity of Vaccine-induced B Cell Responses
Spatial Heterogeneity of Vaccine-induced B Cell Responses
17:00—18:45
Leveraging HIV Prevention Advances for the Cure Agenda
Julie Ake,
Walter Reed Army Institute of Research, USA
Cure Approaches from NHP to Human
Cure Approaches from NHP to Human
*
Marina F. Caskey,
Rockefeller University, USA
bNabs-Eliciting Vaccine Strategies for HIV Cure
bNabs-Eliciting Vaccine Strategies for HIV Cure
Steven G. Deeks,
University of California, San Francisco, USA
Therapeutic Vaccination for HIV Cure
Therapeutic Vaccination for HIV Cure
Caroline Subra,
Henry Jackson Foundation - Military HIV Research Program Walter Reed Army, USA
Short Talk: Impact of ART and VRC01 Antibody Infusion Alone or in Combination during Acute HIV Infection on Immune Cell Activation
Short Talk: Impact of ART and VRC01 Antibody Infusion Alone or in Combination during Acute HIV Infection on Immune Cell Activation
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
17:00—18:45
B Cell Malignancy Checkpoints and Targets of Therapies
*
Christopher C. Goodnow,
Garvan Institute of Medical Research, Australia
*
Jenna Guthmiller,
University of Colorado SOM, USA
Louis M. Staudt,
NCI, National Institutes of Health, USA
Curing Lymphoma by Understanding B Cell Biology
Curing Lymphoma by Understanding B Cell Biology
Sandrine Roulland,
Aix Marseille University, France
B Cell State Heterogeneity and Lymphomagenesis
B Cell State Heterogeneity and Lymphomagenesis
Karin Tarte,
INSERM U917 Université de Rennes 1, France
Follicular Lymphoma Microenvironment: Plasticity and Origin
Follicular Lymphoma Microenvironment: Plasticity and Origin
Jaewoo Choi,
NIH/NCI, USA
Short Talk: Attacking Oncogenic B Cell Receptor Signaling in Lymphoma With Glucocorticoids
Short Talk: Attacking Oncogenic B Cell Receptor Signaling in Lymphoma With Glucocorticoids
Following Session is for B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers (Z5)
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
*Session Chair †Invited, not yet responded.
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
We gratefully acknowledge additional support from these exhibitors at this conference:
|
|
|
|
|
Please stop by to meet these exhibitors during the conference.
We gratefully acknowledge the generous grant for this conference provided by:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: John Monson,
Director of Corporate Relations, Email: johnm@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
